Skip to content

LED microneedle patch compare with intralesional corticosteroid injection for treatment of alopecia areata

LED microneedle patch compare with intralesional corticosteroid injection for treatment of alopecia areata

Status
Unknown
Phases
Phase 3
Study type
Interventional
Source
TCTR
Registry ID
TCTR20240607001
Enrollment
36
Registered
2024-06-07
Start date
2024-04-05
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alopecia areata Alopecia areata

Interventions

Triamcinolone acetonide 5 mg/ mL, 0.X ml per diameter of patch X cm. (e.g. 0.4 ml for patch 4 cm.) inject by needle 30-gauge at lesion,Microneedle patch : round or square shape 1. by National Nanotec
Intralesional corticosteroids injection ,Microneedle patch with Red LED light,Microneedle patch plus corticosteroid,Microneedle patch with Red LED light plus corticosteroid

Sponsors

Chulabhorn International College of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Male and female age 18-60 years old 2. Clinical and trichoscopic diagnosis of patch typed alopecia areata 3. Area of alopecia areata more than or equal to 1 area 4. Diameter of alopecia patch more than or equal to 2 cm. 5. Patient who voluntarily submitted written consent

Exclusion criteria

Exclusion criteria: 1. Receiving any treatment of alopecia areata in the past 6 months including topical, oral, injection, or LED light therapy 2. Having allergic reaction with component of microneedle patch 3. Previous history of syphilis infection 4. Having systemic infection or under systemic antibiotic therapy 5. Having liver diseases, including cirrhosis or liver cancer 6. Having kidney diseases, including renal failure or nephrotic syndrome 7. Having severe acute cardiovascular diseases, including heart failure, myocardial infarction, or stroke 8. Pregnancy or lactating women (screening by last menstrual period. If suspect, urine pregnancy test will be done) 9. Acute diffuse alopecia areata 10. Alopecia totalis, alopecia universalis 11. Ophiasis alopecia 12. Area of alopecia areata more than 50% of the scalp 13. Having bleeding tendency e.g. hemophilia or von Willebrand disease 14. People who are sensitive to light, have epilepsy, or use photo-sensitizing drug

Design outcomes

Primary

MeasureTime frame
Hair regrowth at month 1, 2, 3, 4, 5, 6 Regrowth scale

Secondary

MeasureTime frame
disease activity, new hair regrowth at month 0, 1, 2, 3, 4, 5, 6 Use Dermoscope,Pain at month 0, 1, 2, 3, 4, 5, 6 visual analog scale

Countries

Thailand

Contacts

Public ContactPakveranun Ariyaatthaya

Thammasat university

pakveranun.aa@gmail.com0934423544

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026